Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1–4 in ItalyAda Bertoli, Alessia Ciancio, Massimo Puoti et al.|Scientific Reports|2018Cited by 48
Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical TrialStefano Rusconi, Giulia Marchetti, Paola Vitiello et al.|PLoS ONE|2013Cited by 42
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?Velia Chiara Di Maio, L. Lambiase, Valeria Cento et al.|Journal of Hepatology|2017Cited by 31
Pillars of long-term antiretroviral therapy successLucia Taramasso, Franco Maggiolo, Massimo Andreoni et al.|Pharmacological Research|2023Cited by 22
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona CohortRoberta Gagliardini, Stefano Bonora, S De Benedittis et al.|Journal of Antimicrobial Chemotherapy|2025Cited by 15